阿托伐他汀和瑞舒伐他汀对2型糖尿病患者高敏C反应蛋白和血脂的疗效比较

Effects of Atorvastatin and Rosuvastatin on High-sensitivity C-reactive Protein and Lipid Profile in the Patients with Type 2 Diabetes Mellitus

目的:评估和比较阿托伐他汀和瑞舒伐他汀在2型糖尿病(T2DM)患者中对高敏C反应蛋白(hs-CRP)和血脂水平的作用。方法:T2DM患者44例随机分成阿托伐他汀组(23例,20 mg/d)和瑞舒伐他汀组(21例,10 mg/d),两组均治疗4周,在治疗前、后抽取静脉血送检,比较两组hs-CRP,低密度脂蛋白(LDL-C),高密度脂蛋白(HDL-C),高甘油三酯(TG)和总胆固醇(TC)水平在治疗前、后的变化以及两组的变化程度。结果:两组治疗后hs-CRP、LDL-C、TC和TG水平均显著降低,HDL-C水平显著升高(与治疗前比,P<0.01);两组hs-CRP和TG的降低幅度,以及HDL-C升高幅度无统计学意义,但瑞舒伐他汀组LDL-C和TC的降低程度显著优于阿托伐他汀组(P<0.01)。结论:T2DM患者用瑞舒伐他汀在降低LDL-C和TC方面优于阿托伐他汀,两种药物在降低hs-CRP和其它血脂指标方面效果相同。

Objective： To evaluate and compare the effects of atorvastatin and rosuvastatin on high-sensitivity C-reactive protein（ hs-CRP） levels and lipid profile in type 2 diabetes mellitus（T2DM）patients. Methods： A total of 44 subjects were randomly allocated to two groups. Group atorvastatin was administered with atorvastatin（20 mg/d）and Group rovastatin with rovastatin（ 10 mg/d）treatment for 4 weeks. The parameters studied were hs-CRP and lipid profile comprising LDL-C, HDL-C, TG and TC before and after treatment. Results： The Levels of hs-CRP, LDL-C, TC and TG were decreased, and HDL-C was significantly increased between atorvastatin and rosuvastatin groups. There was no significant difference in effect of atorvastatin and rosuvastatin in decreasing of hs-CRP and TG levels, and increasing HDL-C levels in T2DM patients. The percentage of decreasing LDL-C and TC by rosuvastin was to a greater extent than that caused by atorvastatin in these patients. Conclusion： In T2DM patients, rosuvastatin has better effect than atorvastatin on decreasing LDL-C and TC levels, while no better effect on decreasing hs-CRP and other lipid profile levels.